PharmaVentures advises GPCR Therapeutics on their acquisition of Burixafor

Oxford, UK, 24th November 2020

PharmaVentures today announced it has acted as an advisor to GPCR Therapeutics, Inc (GPCR) providing due diligence for their acquisition of Burixafor targeting CXCR4.

GPCR has signed an exclusive agreement with TaiGen Biotechnology Company Ltd (TaiGen) for the development of Burixafor for worldwide markets.

GPCR Therapeutics is a leading Korean biotechnology company, a world leader in the field of GPCR heteromer science and has proprietary expertise and technology applicable to the development of this class of anti-cancer targets. CXCR4 antagonism is an accepted avenue for cancer therapy and GPCR Therapeutics has significant experience and knowledge that will enable the development of Burixafor in the oncology field.

Dongseung Seen, CEO of GPCR Therapeutics, said, “This collaboration with TaiGen, which is a leading biotech company engaged in innovative molecular-based platforms with strong R&D capabilities, will lead to a long-term strategic and productive partnership. Further, it is our goal that our work together will position us to be a pre-eminent developer of anti-CXCR4 oncology drugs.”

Summer Park, Senior Business Development Director, PharmaVentures said: “In the past decade we’ve seen more exciting innovative technologies coming out of Korea. We are proud to have supported GPCR in this process which has enabled the company to further its aim of developing novel and effective anti-cancer therapies.”

Adrian Dawkes, Managing Director at PharmaVentures, added “South Korea is forging ahead with the internationalisation of its innovative biotechnology sector and we, at PharmVentures, are pleased to be able to bring our knowledge of both Korean and Western cultures to support our Korean clients with their global transactions.”

This partnering deal follows PharmaVentures’ continued successes in working with Korean companies to enable them to expand further into the international market.

About PharmaVentures

PharmaVentures is a premier transaction advisory firm; a world leader in partnering, pharma M&A deals and strategic alliances.

An unrivalled bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes PharmaVentures uniquely placed to support healthcare businesses in all aspects of deal-making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

PharmaVentures Capital Ltd is a wholly owned subsidiary of PharmaVentures Ltd. All regulated activities are delivered through PharmaVentures Capital Ltd, which is authorised and regulated by the Financial Conduct Authority (741356). PharmaVentures Capital Ltd undertakes regulated activities for and on behalf of professional clients only as defined in the FCA handbook COBS 3.5.

Services include:

  • Pharma M&A (divestments, pharma mergers, acquisitions and strategic transactions)
  • Strategy (commercialisation, deal strategy, due diligence, market entry)
  • Valuation and Positioning (licensing, M&A, fundraising & expert testimonies)
  • Licensing (in and out licensing)
  • Expert Testimony (patent infringement, deal disagreements, taxation, determining damages)
  • Private Placement Fundraising

PharmaVentures is based in Oxford, UK, employs over 20 professionals and has associates in N. America, Latin America, Asia-Pacific.

For further information, contact:

Dr Fintan Walton

CEO

PharmaVentures Ltd

+44 1865 332 700

enquiries@pharmaventures.com

PharmaVentures advises Vital Foods on the sale of its Zyactinase-based digestive health product asset portfolio to Mundipharma.

Oxford, England, 6th September 2018

PharmaVentures Ltd (“PharmaVentures”) is pleased to announce that it acted as exclusive adviser to Vital Food Processors Ltd (“Vital Foods”), an agricultural science company founded in New Zealand, on an asset purchase agreement with Mundipharma for the global rights beyond New Zealand to commercialise Zyactinase™ – a clinically-proven gastrointestinal consumer health product.

Zyactinase™is the basis of market leading, natural, plant-based consumer health products for the promotion of digestive health.  Zyactinase™ is a freeze-dried extract of Kiwifruit (Actinidia deliciosa) that has been developed as a constipation relief product as well as for long-term gut health. It contains a protease complex, fiber, pectin and fructo-oligosaccharides that stimulates increased bowel movements.

Under the agreement, Mundipharma will initially focus on the commercialising of Zyactinase™ to establish a foothold in the US and Canada markets, while continuing to supply existing partners. It will then look to expand its marketing and distribution footprint globally.

This agreement will also enable the extension of the company’s Senokot®product range in the US, which is also an all natural, clinically proven digestive health supplement for the treatment of constipation. (see http://www.prnewswire.co.uk/news-releases/mundipharma-closes-acquisition-of-vital-food-processors-limited-assets-and-secures-global-rights-to-692559241.html)

Adrian Dawkes, Managing Director, who led the deal at PharmaVentures, commented; “The consumer health space has seen significant deal activity recently and, not surprisingly, there was a lot of interest in Vital Foods’ assets. We are delighted to have been able to secure this deal with Mundipharma who are ideally placed to maximise the potential of Zyactinase”.

Fintan Walton, Founder and Chief Executive of PharmaVentures said; “We are particularly pleased to have brought PharmaVentures’ broad experience and skills to bear in another cross-border deal where the pairing of high-quality assets from Vital Foods with an ideal acquirer in Mundipharma has resulted in an excellent outcome for all”.

  

PharmaVentures advises SalvaRx Group plc on the acquisition of SalvaRx Ltd by Portage Biotech Inc.

Oxford, UK, 20 August 2018

PharmaVentures Ltd. (“PharmaVentures”) is pleased to announce that it acted as an independent adviser to SalvaRx Group plc (SALV:LSE) (“SalvaRx”) and Portage Biotech, Inc (“Portage”), on the acquisition of its subsidiary SalvaRx Ltd by Portage. Subject to regulatory and shareholder consent, Portage will acquire 100% of SalvaRx Limited for an aggregate consideration of US$71.7 Million. 

SalvaRx is a related party of Portage, the transaction is subject to the requirements of Alberta Securities Commission’s Multilateral Instrument 61-101 Protection of Minority Shareholders in Special Transactions (“MI 61-101”). As a consequence, the Transaction requires minority shareholder approval.

Although the transaction is exempt from the formal valuation requirements of MI 61-101 pursuant to Section 5.5(a) PharmaVentures was commissioned by SalvaRx and Portage to perform an independent valuation (the “Valuation”) of SalvaRx Limited. The Valuation, dated July 23, 2018, provided the parties with, amongst other things, a discussion of various methodologies to value SalvaRx Limited as well as a range of possible values.

For more information see the Portage Biotech press release: https://www.prnewswire.com/news-releases/portage-to-acquire-salvarx-limited-300696910.html.

Adrian Dawkes, Managing Director, PharmaVentures, commented; “We have worked previously with SalvaRx and were pleased to provide our extensive valuation capabilities and market knowledge to assist in this transaction”.

Fintan Walton, Founder and Chief Executive of PharmaVentures said; “PharmaVentures is trusted by long established pharmaceutical companies, governments as well as innovative biotechs like SalvaRx to provide high quality, robust and comprehensively researched valuations to support their key strategic transactions. We are pleased to have assisted SalvaRx in their endeavors”. 

PharmaVentures Strengthens Its First-Class Strategy Consulting & Dealmaking Capabilities

PharmaVentures strengthens its first class healthcare strategy and dealmaking capabilities with the recruitment of a new Vice President, Ashley Cox.

Ashley has built significant industry experience working directly for a number of pharmaceutical companies, undertaking both Project Execution and Business Development activities.  Most notably, she has worked for firms such as Lundbeck, Teva and Glenmark, where she led business development and sales activities across a wide range of products and services.

Fintan Walton, PhD, Chief Executive of PharmaVentures, said: “We are delighted to welcome Ashley to PharmaVentures. She has an impressive track record in healthcare strategy consulting and dealmaking. Her wealth of experience will add significant value to our clients in their dealmaking and commercial strategy activities”.

 

Most recently, Ashley worked with SmartAnalyst, Inc., as the Senior Director, European Business Development supporting Global Pharmaceutical and Biotech clients in their disease, asset and portfolio strategy development. Previously, Ashley was Head of Global Business Development for the Prescient Healthcare Group, with a strong focus on Competitive Intelligence and Business Analytics.  Ashley has supported decision making in the majority of the top 20 pharma companies and many biotech companies. She started her career as a Medical Representative and has held a variety of commercial and licensing roles across the pharmaceutical and generics sectors.

Ashley received a BSc. (Hons). in Neuroscience from the University of Glasgow and a Masters in Pharmaceutical Analysis from the University of Strathclyde.

PharmaVentures Capital Ltd advises Biosceptre International Ltd, a clinical stage oncology company, on its Series A private placement by Tuspark S&T

PharmaVentures Capital Limited is pleased to announce that it acted as adviser to Biosceptre International Limited (“Biosceptre”) for the successful Series A private placement from the Chinese conglomerate Tuspark Science & Technology Service Group (Tuspark) through its investment vehicle, Bluesky Partnership II L.P. As Tuspark’s first major overseas investment into biotech, this represents a strong belief in the Biosceptre team and the potential transformative effects their therapies may bring to cancer patients. <!–break–>

Biosceptre’s therapies are focused upon a novel cancer target, nfP2X7, that is completely absent in healthy tissue, but present on tumour tissue in the majority of cancers, including lung, breast, colorectal and prostate. For more information on Biosceptre’s therapies see http://www.biosceptre.com/pipeline/.

This first institutional raise will allow Biosceptre to advance its three oncology clinical assets which are BIL010t, a polyclonal antibody ointment for the topical treatment of non-melanoma skin cancers, BIL06v, a peptide protein conjugate and BIL03s, fully human domain monoclonal, both for systemic uses targeting solid and blood cancers. Clinical trials are being planned in Australia, UK and EU.

Fintan Walton, Chairman and Chief Executive of PharmaVentures, said: “This investment by the Chinese company Tuspark S&T in Biosceptre represents a significant landmark for both the UK Biotechnology sector and PharmaVentures Capital Limited.”

Adrian Dawkes, Managing Director at PharmaVentures, added; “As a long-standing client, PharmaVentures is pleased to have advised Biosceptre on this transaction. We are delighted to have been able to leverage our relationships in China to secure this investment for the company.”

For the past 25 years, PharmaVentures has acted as an advisor to over 700 global pharmaceutical and biotechnology clients in transactions; many covering licensing, mergers, acquisitions, divestments and joint venture activities for companies.

About Biosceptre International

Biosceptre is a Cambridge, UK headquartered biotechnology company focused on developing next generation cancer treatments targeting nfP2X7, an oncology target with exquisite specificity.

Sir Gregory Winter, Founder of Domantis and Cambridge Antibody Technologies, is the Acting Chairman of the Biosceptre Board of Directors and he also chairs the company’s Science Advisory Board.

Biosceptre’s clinical programs include systemic antibody-based therapeutics and vaccines, intended to treat a significant range of cancer types. With one successful Phase I trial completed, Biosceptre will be progressing a number of clinical trials across a range of cancer indications. These trials will seek to further advance the establishment of nfP2X7 as a new and important target for the successful treatment of a range of human cancers.

About Tus-Holdings

Tus-Holdings is a large integrated enterprise established in reliance on Tsinghua University. It takes full responsibility for developing, constructing, operating and managing the Tsinghua University Science Park, and is one of the first National Demonstration Enterprises in modern service industry. It is the controlling shareholder of over 500 listed & non-listed enterprises, and the total assets under its management have exceeded GBP 15 billion. Tus-S&T Service Group is the equity investment platform of Tus-Holdings, who directly lead this cooperation.

This Press release is issued by PharmaVentures Capital Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) and is for information purposes only. This communication does not constitute an offer or solicitation to purchase or engage in any investment products, securities or services and should not be deemed as such.